Computational Insights into Intranasal Drug Delivery: Enhancing Outcomes in Pediatric Cystic Fibrosis.
Authors
Affiliations (5)
Affiliations (5)
- Department of Biotechnology, Faculty of biological sciences, Alzahra university, Tehran, Iran; School of Biotechnology and Biomolecular Sciences, University of New South Wales (UNSW), Sydney, Australia.
- Department of Mechanical Engineering, K. N. Toosi University of Technology, Tehran, Iran.
- Department of Biotechnology, Faculty of biological sciences, Alzahra university, Tehran, Iran.
- School of Biotechnology and Biomolecular Sciences, University of New South Wales (UNSW), Sydney, Australia; Biomedical AI Laboratory (Vafaee Lab), Sydney, Australia.
- Department of Pediatric Pulmonology, Mofid Children's Hospital, Shahid Beheshti University of Medical.
Abstract
The significant global health threat of antimicrobial resistance is particularly noted among patients with cystic fibrosis, who experience increased morbidity and mortality due to persistent bacterial infections. The present research explores the feasibility of utilizing intranasal administration to improve the therapeutic effectiveness of antibiotics in individuals with cystic fibrosis (CF). This approach leverages the unique anatomical and physiological features of the nasal cavity for targeted drug delivery. Computational fluid dynamics (CFD) was employed to model drug deposition patterns in three demographic groups: a healthy adult aged 37, a healthy child aged 5, and a 6-year-old pediatric cystic fibrosis (CF) patient exhibiting nasal cavity structural anomalies. CT scan imaging was utilized to reconstruct nasal geometries, and airflow, particle trajectories, and deposition rates were analyzed across different breathing patterns, spray angles, and particle sizes. Machine learning models were developed as surrogate predictors of regional doses based on CFD simulations. The results emphasize the critical role of anatomical differences in optimizing intranasal drug delivery strategies, underscoring the necessity for tailored approaches in pediatric populations, especially for those with cystic fibrosis, to combat the escalating issue of antimicrobial resistance effectively. Insights into enhancing antibiotic delivery are provided to improve treatment outcomes and mitigate resistance development in vulnerable patient groups.